Form 4: Immix Biopharma Director Jason Hsu Reports Stock Option Grants and Beneficial Ownership

Director Jason Hsu reports stock option grants and beneficial ownership of Immix Biopharma shares, including holdings through VERITAS LIBERABIT VOS, LLC and Signature Collection Properties, LLC.

Summary

• On May 20, 2024, Jason Hsu, a director of Immix Biopharma, Inc., filed a Form 4 detailing changes in his beneficial ownership of the company's securities.
• The report indicates that Hsu was granted stock options to purchase 21,587 and 25,512 shares of common stock at an exercise price of $2.47 on May 15, 2024, which replace prior awards held in Nexcella, Inc. in contemplation of the merger of Nexcella, Inc. and Immix Biopharma, Inc., which became effective on May 20, 2024.
• The stock options vest in thirteen equal monthly installments following the date of grant, subject to Hsu's continued service with the Issuer.
• Hsu directly owns 813,000 shares of Immix Biopharma common stock.
• He also indirectly owns 3,915,913 shares through VERITAS LIBERABIT VOS, LLC and 50,000 shares through Signature Collection Properties, LLC.
• Hsu disclaims beneficial ownership of the shares held by these entities except to the extent of his pecuniary interest.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing. The granting of stock options is generally viewed as neutral to slightly positive, aligning management's interests with shareholders.

Positives

• The granting of stock options to a director can be seen as a positive sign, aligning the director's interests with those of the shareholders.
• The vesting schedule encourages continued service and commitment from the director.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing is triggered by the granting of stock options and the merger of Nexcella, Inc. and Immix Biopharma, Inc.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the biopharmaceutical industry.
• The vesting schedule of thirteen months is fairly standard for such grants.
• The reporting of beneficial ownership through LLCs is also a common practice for high-net-worth individuals.

Stakeholder Impact

• Shareholders may view the stock option grants as a sign of confidence in the company's future.
• Employees may be motivated by the fact that key personnel are incentivized to improve company performance.

Key Dates